Rituximab and Belimumab for Lupus Nephritis

(

CALIBRATE

)

ITN Protocol #:

ITN055AI

Branded Name:

CALIBRATE

ClinicalTrials.Gov ID:

NCT02260934

Treatment Protocol #:

Therapeutic Area:

Autoimmune Disease

Current Status:

Complete

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Rituximab Plus Cyclophosphamide followed by Belimumab for the Treatment of Lupus Nephritis

Clinical Operations Associate Director

Clinical Operations Manager

ITN Biologist

ITN Biostat

ITN Clinical Trial Physician

NIAID Project Manager

Rho Data Manager

Rho Scientist

Study Personnel:

Protocol Chair

Cynthia Aranow, MD caranow@nshs.edu

Work:

516-562-3837

Protocol Chair

Maria Dall’Era, MD maria.dallera@ucsf.edu

Work:

415-476-0783

Protocol Chair

David Wofsy, MD wofsyd@medsch.ucsf.edu

Work:

415-750-2104

Protocol Chair

Patti Tosta ptosta@immunetolerance.org

Work:

415-353-4421

Protocol Chair

Kristin Ryker kryker@immunetolerance.org

Work:

415-353-4405

Protocol Chair

Kristina Harris, PhD

Work:

Protocol Chair

Noha Lim, PhD nlim@immunetolerance.org

Work:

240-235-6151

Protocol Chair

Dawn Smilek, MD PhD dsmilek@immunetolerance.org

Work:

415-353-4308

Protocol Chair

Wendy Gao gaowe@mail.nih.gov

Work:

240-627-3471

Protocol Chair

LaSonia Morgan LaSonia_Morgan@rhoworld.com

Work:

919-595-6379

Protocol Chair

James Rochon, PhD james_rochon@rhoworld.com

Work:

919-595-6857